EC 232-317-7
FB102, a CD122 inhibitor, met the primary histology endpoint (Vh:Cd change; p=0.0176) versus placebo and showed aligned symptom and inflammatory benefits with no new safety signals.
A subscription lists every plant we track for glutens, with its owners and capacity. What a subscription does →
